NCT00679783 - Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 8, 2008

Primary Completion Date

March 26, 2010

Study Completion Date

July 20, 2022

Conditions

Ovarian CarcinomaBreast Cancer

Interventions

DRUG

AZD2281

PARP inhibitor Olaparib tablets, oral

Trial Locations (6)

Research Site, Edmonton

Research Site, Vancouver

Research Site, Halifax

Research Site, Hamilton

Research Site, Toronto

Research Site, Montreal